Fully humanized anti-CD20 recombinant antibody

A recombinant antibody, fully human technology, applied in recombinant DNA technology, antibody mimic/scaffold, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, etc., can solve the problem of lack of Fc segment function
CN110386983AActive Publication Date: 2019-10-29武汉雁达生物技术有限公司
5 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
武汉雁达生物技术有限公司
Publication Date
2019-10-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an anti-CD20 single chain antibody having a heavy chain variable region amino acid sequence as shown in SEQ ID No:2 and a light chain variable region amino acid sequence as shown in SEQ ID No:3. The invention further discloses a fully humanized anti-CD20 recombinant antibody, which comprises the single chain antibody and a human antibody constant region Fc fragment, the amino acid sequence of the recombinant antibody is as shown in SEQ ID No:17. The invention further discloses an eukaryotic expression vector. The eukaryotic expression vector is obtained by inserting thesequence of the anti-CD20 singlechain antibody into a universal expression vector sp-Fc / pcDNA3.1, and the nucleic acid sequence of the universal expression vector is as shown in SEQ ID No:18. The invention further discloses a recombinant expression vector.The eukaryotic expression vector is used as a template, an amplification primer is used for amplifyinga fragment sp-scFv966-Fc, and the obtained amplified fragment is inserted into a pMH3 vector.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of antibody engineering, in particular to a fully human anti-CD20 recombinant antibody. Background technique

[0002] In recent years, biomedicine has revolutionized the pharmaceutical industry, bringing new hope to patients who have failed traditional treatments or previously had no treatment options. The development of monoclonal antibody drugs has gone through four stages: murine monoclonal antibody, chimeric monoclonal antibody, humanized monoclonal antibody and fully human monoclonal antibody. The traditional production of monoclonal antibodies relies on the immunization of laboratory animals and subsequent screening of specific hybridoma cells. This method is time-consuming, laborious, and costly to obtain antibodies, and its effectiveness depends on the ability of the immune system to produce humoral immunity to potential antigens. Ability is limited by many conditions. The emergence of recombinant ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More